Who are Deepmatter?

Deepmatter is a big data and analysis company focused on enabling reproducibility and predictability in chemistry.

We develop hardware and software to deliver applications resulting in new optimised chemicals, materials and formulations in commercially significant areas such as pharmaceutical research, fine chemicals, scientific publications and teaching.

We’re at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine.

THE VALUE OF DIGITIZING CHEMISTRY

The digitization of chemistry is an unprecedented enabler and generator of value for the billion dollar chemistry industry.

Digitized chemistry enhances reproducibility and increases productivity. The contextualized data generated by DeepMatter provides greater access to high fidelity data and informs and improves better outcomes.

DeepMatter drives down costs and improves efficiency in both discovery and manufacturing, making the chemistry industry more sustainable and profitable.

DeepMatter is making chemistry more playable than ever before.

INFOCHEM

In 2019, DeepMatter Group acquired InfoChem, based in Munich, Germany. Infochem has more than 30 years’ experience in the development and integration of sophisticated software tools for the storage and handling of structure and reaction information. The company’s main activities involve the production of synthesis planning and reaction prediction solutions and the automatic extraction of scientific information from text and images. The integration of InfoChem will accelerate development towards our end goal: the digitization of chemistry.

Advised by experts

Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.

Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.

Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

OUR TEAM

We are a multidisciplinary team of big data, software, chemistry and hardware engineers.

We share a passion for combining technology and Artificial Intelligence (AI) to maximise the return on investment made in chemistry every year.

MAIN BOARD LEADERSHIP TEAM

Mark Warne

Chief Executive

Lauren Lees

Finance Director

Laurence Ede

Non-Executive Director

Bettina Goerner